Updated T2DM treatment guidelines promote the use of sodium-glucose transporter 2 (SGLT2) inhibitors as well as glucagon-like peptide-1 (GLP-1) receptor agonists in subjects at high cardiovascular risk or with known cardiovascular disease [7, 8]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.